Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RISANKIZUMAB-RZAA Cause Liver function test increased? 89 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 89 reports of Liver function test increased have been filed in association with RISANKIZUMAB-RZAA. This represents 0.1% of all adverse event reports for RISANKIZUMAB-RZAA.

89
Reports of Liver function test increased with RISANKIZUMAB-RZAA
0.1%
of all RISANKIZUMAB-RZAA reports
3
Deaths
32
Hospitalizations

How Dangerous Is Liver function test increased From RISANKIZUMAB-RZAA?

Of the 89 reports, 3 (3.4%) resulted in death, 32 (36.0%) required hospitalization, and 1 (1.1%) were considered life-threatening.

Is Liver function test increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RISANKIZUMAB-RZAA. However, 89 reports have been filed with the FAERS database.

What Other Side Effects Does RISANKIZUMAB-RZAA Cause?

Psoriasis (6,896) Drug ineffective (2,885) Pain (2,584) Fatigue (2,483) Arthralgia (2,419) Pruritus (2,311) Covid-19 (2,145) Death (1,700) Fall (1,666) Surgery (1,662)

What Other Drugs Cause Liver function test increased?

METHOTREXATE (3,839) ADALIMUMAB (2,070) ETANERCEPT (1,829) LEFLUNOMIDE (1,521) ABATACEPT (1,415) TOCILIZUMAB (1,406) RITUXIMAB (1,325) SULFASALAZINE (1,263) HYDROXYCHLOROQUINE (1,259) TOFACITINIB (1,221)

Which RISANKIZUMAB-RZAA Alternatives Have Lower Liver function test increased Risk?

RISANKIZUMAB-RZAA vs RISDIPLAM RISANKIZUMAB-RZAA vs RISEDRONATE RISANKIZUMAB-RZAA vs RISEDRONIC ACID RISANKIZUMAB-RZAA vs RISPERDAL RISANKIZUMAB-RZAA vs RISPERDAL CONSTA

Related Pages

RISANKIZUMAB-RZAA Full Profile All Liver function test increased Reports All Drugs Causing Liver function test increased RISANKIZUMAB-RZAA Demographics